Any statement describing a goal, expectation ,
intention or belief of the Company is a forward-looking statement and
should be considered an at-risk statement. The
actual results may differ materially from those contained in this
press release.
The webcast will be archived at the Company's website for 30 days
following the presentation . Sabin Vaccine Institute, United States Department of
Agriculture and Bill + Melinda Gates Foundation .

newsweekly mdtv

Hollis-Eden Pharmaceuticals to Present at Rodman + Renshaw Global Healthcare Conference

Heymann also addressed polio, which is the next disease targeted for
global eradication.

Contact: Mary K.

tuberculosis ramex

S. Such statements are subject
to certain risks and uncertainties, including the ability to
successfully complete preclinical and clinical trials within specified
timelines, if at all; the ability to obtain regulatory approval for
NEUMUNE, even if shown to be effective in preclinical studies; the
ability to receive any stockpiling orders for NEUMUNE from the U. is a development-stage
pharmaceutical company based in San Diego, California, working to
become the world leader in the development of a new class of
investigational drugs known as immune regulating hormones (IRHs). "While eradication of smallpox and
the incredible progress we've made against polio worldwide are the most
prominent examples of vaccine successes, literally dozens of other diseases
would claim many millions of lives annually if not for vaccines. Nichol, MD, MPH, MBA, professor of medicine at University
of Minnesota and chief of medicine and director of primary and subspecialty
medicine service line, VA Medical Center, in Minneapolis.

bna scicentral

and foreign governments, even if approved by regulatory authorities;
the Company's future capital needs; the Company's ability to obtain
additional funding; the ability of the Company to protect its
intellectual property rights and to not infringe the intellectual
property rights of others; the development of competitive products by
other companies; and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. For more information on Hollis-Eden, contact the
Company's website at www.

reuters indepth

government
under Project BioShield for medical countermeasures against weapons of
mass destruction.

(NASDAQ:HEPH) today announced that it will
present at the Rodman + Renshaw Techvest 2nd Annual Global Healthcare
Conference in Paris, France at 5:55 a.

National Foundation for Infectious Diseases Kicks off Eighth Annual Conference on Vaccine Research

intelihealth tuberculosis

Potential funding strategies include "pull"
mechanisms, such as advance purchase contracts that guarantee markets
and incentivize industry to invest in the development of new vaccines
and therapies for global infectious diseases. These contracts could be
similar to those being awarded to industry by the U. The
webcast will be archived at the Company's website for 30 days
following the presentation. The
actual results may differ materially from those contained in this
press release. The
National Foundation for Infectious Diseases' Annual Conference on Vaccine
Research (ACVR) will run from May 9 to 11 in Baltimore, Maryland. Charles
Merieux Award is made possible by an unrestricted educational grant to NFID by
sanofi pasteur.

alphagalileo fibrosis

holliseden.World Health Organization's David Heymann Addresses Dilemmas in Global Public
Health

BALTIMORE, The world's largest scientific meeting
devoted exclusively to research on vaccines and associated technologies for
disease prevention and treatment through immunization was kicked off with a
keynote address by the World Health Organization's David Heymann , MD. Intensive efforts are underway in these countries, and the
possibility of containing the imported virus is high. While recent
intensification of global polio immunization efforts makes it feasible that
transmission could be halted by the end of 2005, it also leads to a dilemma --
the trivalent oral polio vaccine being used for eradication worldwide would
become the only source of polio (vaccine derived polio viruses (VDVP) or
vaccine-associated paralytic polio), requiring that its use be discontinued .

crain mdtv

holliseden.com.

About NFID's Annual Conference on Vaccine Research
NFID's vaccine research conference provides high-quality, current reports
of scientific progress featured in both invited presentations and submitted
abstracts that address the most recent scientific advances contributing to
progress in the development of vaccines and that identify research
opportunities and scientific challenges associated with vaccine development,
production and distribution.

Founded in 1973, NFID is a non-profit organization dedicated to public and
professional educational programs about infectious diseases.

fibrosis headlinespot

newsweek headline

HIV, Malaria + TB," is sponsored
by BIO Ventures for Global Health. For more information on Hollis-Eden, contact the
Company's website at www.

Business Editors/Health /Medical Writers
Rodman + Renshaw Techvest Global Healthcare Conference 2005

SAN DIEGO----Hollis -Eden
Pharmaceuticals, Inc.S.

All sites providing information pertaining to news and current events related to Health.

fibrosis ramex

The Business Roundtable, "Strategies for Creating a
Real Market for Neglected Diseases.
"The breadth of vaccine research covered at this meeting is truly
extraordinary ," noted Dr.

newsfeed approvals

eastern standard time on Thursday, February 24, 2005.S.
"The significant contribution of vaccines to improved public health is
indisputable," according to Dr.
In its place a new vaccine , a monovalent polio vaccine, now provides greater
immunity with fewer doses, increasing the feasibility of reaching the year end
target of interrupting transmission.

allafrica newsweek

m.
Hollis-Eden Pharmaceuticals, Inc .com

This press release contains forward-looking statements concerning
the potential and prospects of the Company's drug discovery program
and its drug candidates. Such statements are subject
to certain risks and uncertainties, including the ability to
successfully complete preclinical and clinical trials within specified
timelines, if at all; the ability to obtain regulatory approval for
NEUMUNE , even if shown to be effective in preclinical studies; the
ability to receive any stockpiling orders for NEUMUNE from the U.

headline reuters

allafrica reuters

is a development-stage
pharmaceutical company based in San Diego, California , working to
become the world leader in the development of a new class of
investigational drugs known as immune regulating hormones (IRHs). Presenting on behalf of the
Company will be Daniel D .

headline headlinespot

Investors may access the webcast under "Event Calendar" on the
Investors section of Hollis-Eden 's website at www. The
goal of IRH therapy is to direct, through controlling gene expression,
the production of key cytokines and enzymes that re-regulate immune
and metabolic functions toward homeostasis , a profile that could be
useful in a wide variety of diseases. Hollis-Eden is also developing IRHs for protection from
chemotherapy and other conditions of immune dysregulation such as
autoimmunity .holliseden.
and foreign governments, even if approved by regulatory authorities;
the Company's future capital needs; the Company's ability to obtain
additional funding; the ability of the Company to protect its
intellectual property rights and to not infringe the intellectual
property rights of others; the development of competitive products by
other companies; and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. Heymann."
At this year's ACVR, the NFID presented the first Dr.

crain newsweekly

He also addressed the challenges of vaccine discovery and the need for
intensified research and development of new vaccines to combat newly emerging
diseases such as Severe Acute Respiratory Syndrome (SARS) and avian influenza. Rehm , NFID's Medical Director. The award, which is
presented to individuals with a demonstrated commitment to science-based
medicine and research in infectious diseases, honors excellence in clinical
and research activities and dedication to public health.

newsweekly findarticles

Pharmaceutical Writers/Business Editors /Economics + Financial
Writers
BIO CEO + Investor Conference 2005

SAN DIEGO----Hollis-Eden
Pharmaceuticals, Inc.
Hollis, Chairman and CEO, will discuss innovative public/private
partnership funding strategies for global infectious diseases on a
Business Roundtable at the BIO CEO + Investor Conference in New York
City on February 23, 2005. A live webcast
of the corporate presentation will be available from the conference.

intelihealth looksmart

(NASDAQ:HEPH) today announced that Richard B.. eastern time (11:55 a. A
live webcast of the presentation will be available from the
conference. Any statement describing a goal, expectation,
intention or belief of the Company is a forward-looking statement and
should be considered an at-risk statement.

crain biologics

Mr. The Company has a number of
investigational compounds under development, including NEUMUNE(TM),
which the Company is developing for use in protection from Acute
Radiation Syndrome (ARS); PHOSPHONOL(TM), a non-IRH candidate for
providing protection against DNA mutations from radiation exposure and
chemotherapy treatment; and IMMUNITIN(TM), which has shown activity in
a variety of infectious diseases, including HIV/AIDS, tuberculosis and
malaria .m. Charles Merieux
Award to Kristin L. The Dr.

newsfeed mdtv

holliseden. Hollis-Eden is also developing IRHs for protection from
chemotherapy and other conditions of immune dysregulation such as
autoimmunity . Investors may access the webcast under "Event Calendar" on
the Investors section of Hollis-Eden 's website at www. The Company has a number of
investigational compounds under development, including NEUMUNE(TM),
which the Company is developing for use in protection from Acute
Radiation Syndrome (ARS); PHOSPHONOL(TM), a non-IRH candidate for
providing protection against DNA mutations from radiation exposure and
chemotherapy treatment; and IMMUNITIN(TM), which has shown activity in
a variety of infectious diseases, including HIV/AIDS, tuberculosis and
malaria. Heymann, who represents the WHO's director general on polio
eradication and was formerly executive director of WHO's communicable diseases
cluster, addressed a broad range of current global public health concerns.
NFID's Annual Conference on Vaccine Research is held in collaboration with
the Centers for Disease Control and Prevention, Center for Biologics
Evaluation and Research of the Food and Drug Administration , Center for
Vaccine Development of the University of Maryland, Fondation Merieux,
International Society for Vaccines, International Vaccine Institute, National
Institute for Allergy and Infectious Diseases, The Netherlands Vaccine
Institute, Albert B.

findarticles newsweek

Hollis-Eden Pharmaceuticals CEO to Participate in Global Disease Funding Panel and Deliver Corporate Presentation at BIO CEO + Investor Conference 2005

Hollis-Eden Pharmaceuticals, Inc. The
goal of IRH therapy is to direct, through controlling gene expression,
the production of key cytokines and enzymes that re-regulate immune
and metabolic functions toward homeostasis, a profile that could be
useful in a wide variety of diseases. He noted during the past 20 months, polio has spread to
16 polio-free countries from West Africa, the most recent being Yemen and
Indonesia.

fibrosis circumcision

Hollis also will be a corporate presenter at 12:00 p.com

This press release contains forward-looking statements concerning
the potential and prospects of the Company 's drug discovery program
and its drug candidates.m. Burgess, Chief Operating Officer and CFO. The live-virus smallpox vaccine cannot be given to those with
significant immunodeficiency because virus replication is enhanced in these
persons, increasing the risk of personal illness and disease transmission to
other unprotected persons. Moore, 212-886-2206

looksmart indepth

com.
Highlights of his presentation included a discussion about how, had
smallpox not been eradicated before the emergence of HIV, it might still be a
threat today.
Dr. Susan J.

mdtv datamonitor

central European time) on May 4, 2005."
Dr. "This
year's agenda covered everything from vaccine supply to agricultural
bioterrorism to development of preventive and therapeutic vaccines for
diseases including malaria, Alzheimer's , hepatitis C, diabetes and human
papilloma virus.